Your browser doesn't support javascript.
loading
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.
Wang, X; Lamberti, G; Di Federico, A; Alessi, J; Ferrara, R; Sholl, M L; Awad, M M; Vokes, N; Ricciuti, B.
Afiliación
  • Wang X; Harvard T.H. Chan School of Public Health, Boston.
  • Lamberti G; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Di Federico A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Alessi J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Ferrara R; University Vita-Salute San Raffaele, Milan; Department of Medical Oncology, IRCCS San Raffaele, Milan, Italy.
  • Sholl ML; Department of Pathology, Brigham and Women's Hospital, Boston.
  • Awad MM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Vokes N; Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, USA.
  • Ricciuti B; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Electronic address: biagio_ricciuti@dfci.harvard.edu.
Ann Oncol ; 35(6): 508-522, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38537779
ABSTRACT
Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations in a tumor's genome. TMB has emerged as a predictor of response to immune checkpoint inhibitors (ICIs) in various cancer types, and several studies have shown that patients with high TMB have better outcomes when treated with programmed death-ligand 1-based therapies. Recently, the Food and Drug Administration has approved TMB as a companion diagnostic for the use of pembrolizumab in solid tumors. However, despite its potential, the use of TMB as a biomarker for immunotherapy efficacy is limited by several factors. Here we review the limitations of TMB in predicting immunotherapy outcomes in patients with cancer and discuss potential strategies to optimize its use in the clinic.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Antígeno B7-H1 / Inhibidores de Puntos de Control Inmunológico / Mutación / Neoplasias Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Antígeno B7-H1 / Inhibidores de Puntos de Control Inmunológico / Mutación / Neoplasias Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido